Untargeted Metabolomics of Plasma From Coronavirus Disease 2019 Patients One Year After Recovery

Xutong ZHANG; Yehong YANG; Yue WU; Rong HAN; Qiaochu WANG; Tao DING; Jiangfeng LIU; Juntao YANG

doi:10.3881/j.issn.1000-503X.16347

PDF(2559 KB)

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (4) : 519-526. DOI: 10.3881/j.issn.1000-503X.16347

Original Articles

Untargeted Metabolomics of Plasma From Coronavirus Disease 2019 Patients One Year After Recovery

Author information +

History +

Abstract

Objective To investigate the recovery of plasma metabolism in asymptomatic and mild patients of coronavirus disease 2019(COVID-19)one year after recovery.Methods A total of 174 participants were recruited from the communities in Wuhan,including 80 healthy volunteers and the COVID-19 patients who had recovered for one year.According to the disease severity,the recovered COVID-19 patients were grouped as asymptomatic patients(n=80)and mild patients(n=14).The liquid chromatography mass spectrometry platform was employed to study the metabolomic characteristics of the plasma from all the participants.Results The plasma metabolites in asymptomatic patients and mild patients remained abnormal compared with those in healthy volunteers.Among the differential metabolites in asymptomatic patients and mild patients,some metabolites showed a downward trend only in mild patients,such as phosphatidylethanolamine[20∶3(5Z,8Z,11Z)/P-18∶0],sphingomyelin(d18∶1/24∶0),and cholesteryl(15∶0).The metabolic pathway involving the differential metabolites in mild patients was mainly glycerophospholipid metabolism.Conclusions Even one year after recovery,the mild COVID-19 patients still exhibit metabolic abnormalities.Hence,these patients may experience an extended period of time for recovery.

Key words

severe acute respiratory syndrome coronavirus 2 / coronavirus disease 2019 / untargeted metabolomics / recovery

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Xutong ZHANG , Yehong YANG , Yue WU , et al . Untargeted Metabolomics of Plasma From Coronavirus Disease 2019 Patients One Year After Recovery[J]. Acta Academiae Medicinae Sinicae. 2025, 47(4): 519-526 https://doi.org/10.3881/j.issn.1000-503X.16347

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human:a descriptive study[J]. Chin Med J(Engl), 2020, 133(9):1015-1024.DOI:10.1097/CM9.0000000000000722. Cited in this article [1]

[2]	Li ZB, Liu J, Zhang SQ, et al. Novel potential metabolic biomarker panel for early detection of severe COVID-19 using full-spectrum metabolome and whole-transcriptome analyses[J]. Signal Transduct Target Ther, 2022, 7(1):129.DOI:10.1038/s41392-022-00976-2. Cited in this article [1]

[3]	Borczuk AC, Salvatore SP, Seshan SV, et al. COVID-19 pulmonary pathology:a multi-institutional autopsy cohort from Italy and New York city[J]. Mod Pathol, 2020, 33(11):2156-2168.DOI:10.1038/s41379-020-00661-1. Cited in this article [1]

[4]

Tenforde

, Kim

, Lindsell

, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States,March-June 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(30):993-998.DOI:10.15585/mmwr.mm6930e1.

Cited in this article [1]

[5]	Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19:a longitudinal cohort study[J]. Lancet Respir Med, 2022, 10(9):863-876.DOI:10.1016/s2213-2600(22)00126-6. Cited in this article [1]

[6]	Shi D, Yan R, Lv L, et al. The serum metabolome of COVID-19 patients is distinctive and predictive[J]. Metabolism, 2021,118:154739.DOI:10.1016/j.metabol.2021.154739. Cited in this article [2]

[7]	Hasan MR, Suleiman M, Perez-Lopez A. Metabolomics in the diagnosis and prognosis of COVID-19[J]. Front Genet, 2021,12:721556.DOI:10.3389/fgene.2021.721556. Cited in this article [1]

[8]	Shen B, Yi X, Sun Y, et al. Proteomic and metabolomic characterization of COVID-19 patient sera[J]. Cell, 2020, 182(1):59-72.e15.DOI:10.1016/j.cell.2020.05.032. Cited in this article [1]

[9]	Harry C, Sanara R, Joseph N, et al.. Long covid-mechanisms,risk factors,and management[J]. BMJ, 2021,374:n1648.DOI:10.1136/bmj.n1648. Cited in this article [1]

[10]	Trisha G, Manoj S, Alice P, et al. Long COVID:a clinical update[J]. Lancet, 2024, 404(10453):707-724.DOI:10.1016/S0140-6736(24)01136-X. Cited in this article [1]

[11]	Eckhardt M, Hultquist JF, Kaake RM, et al. A systems approach to infectious disease[J]. Nat Rev Genet, 2020, 21(6):339-354.DOI:10.1038/s41576-020-0212-5. Cited in this article [1]

[12]	Zhang S, Luo P, Xu J, et al. Plasma metabolomic profiles in recovered COVID-19 patients without previous underlying diseases 3 months after discharge[J]. J Inflamm Res, 2021, 14:4485-4501.DOI:10.2147/JIR.S325853. Cited in this article [2]

[13]	Xu J, Zhou M, Luo P, et al. Plasma metabolomic profiling of patients recovered from coronavirus disease 2019(COVID-19)with pulmonary sequelae 3 months after discharge[J]. Clin Infect Dis, 2021, 73(12):2228-2239.DOI:10.1093/cid/ciab147. Cited in this article [4]

[14]	Sparks R, Lau WW, Liu C, et al. Influenza vaccination reveals sex dimorphic imprints of prior mild COVID-19[J]. Nature, 2023, 614(7949):752-761.DOI:10.1038/s41586-022-05670-5. Cited in this article [1]

[15]	Wu J, Zhao M, Li C, et al. The SARS-CoV-2 induced targeted amino acid profiling in patients at hospitalized and convalescent stage[J]. Biosci Rep, 2021, 41(3):BSR20204201.DOI:10.1042/BSR20204201. Cited in this article [1]

[16]	Acosta-Ampudia Y, Monsalve DM, Rojas M, et al. COVID-19 convalescent plasma composition and immunological effects in severe patients[J]. J Autoimmun, 2021,118:102598.DOI:10.1016/j.jaut.2021.102598. Cited in this article [1]

[17]	More TH, Mozafari B, Martens A, et al. Plasma metabolome alterations discriminate between COVID-19 and Non-COVID-19 pneumonia[J]. Metabolites, 2022, 12(11):1058.DOI:10.3390/metabo12111058. Cited in this article [1]

[18]	Li H, Li X, Wu Q, et al. Plasma proteomic and metabolomic characterization of COVID-19 survivors 6 months after discharge[J]. Cell Death Dis, 2022, 13(3):235.DOI:10.1038/s41419-022-04674-3. Cited in this article [1]

[19]	Oliveira LB, Mwangi VI, Sartim MA, et al. Metabolomic profiling of plasma reveals differential disease severity markers in COVID-19 patients[J]. Front Microbiol, 2022,13:844283.DOI:10.3389/fmicb.2022.844283. Cited in this article [5]

[20]	Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-related liver functional abnormality[J]. Clin Gastroenterol Hepatol, 2020, 18(7):1561-1566.DOI:10.1016/j.cgh.2020.04.002. Cited in this article [1]

[21]	Zhang C, Shi L, Wang FS. Liver injury in COVID-19:management and challenges[J]. Lancet Gastroentepol, 2020, 5(5):428-430.DOI:10.1016/s2468-1253(20)30057-1. Cited in this article [1]